Freedman RA, et al. - A total of 49 candidates were studied to assess the consequences of evidence-based treatments for metastatic, human epidermal growth factor receptor 2 (HER2)–positive breast cancer to the CNS. They noticed 49%, the composite CNS objective response rates (ORR) in cohort 3A and 33%, the CNS ORR in cohort 3B. They noted median progression-free survival of 5.5 and 3.1 months in cohorts 3A and 3B, respectively with median survival, 13.3 and 15.1 months in the respective cohorts. They observed diarrhea, the most common grade 3 toxicity among both the cohorts. They suggested neratinib plus capecitabine active against refractory, HER2-positive breast cancer brain metastases. They also implied the enhancement of potency of HER2-directed therapy in the brain by chemotherapy.